Related Experiment Video
Updated: Feb 27, 2026
Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
Published on: August 28, 2021
Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer
Ekaterina Mostovenko1, Yanhong Liu2,3, E Susan Amirian2
1Department of Anatomy, Virginia Commonwealth University , 1217 E. Marshall St., Richmond, Virginia 23284 United States.
Abstract:
Primary brain tumors are predominantly malignant gliomas. Grade IV astrocytomas (glioblastomas, GBM) are among the most deadly of all tumors; most patients will succumb to their disease within 2 years of diagnosis despite standard of care. The grim outlook for brain tumor patients indicates that novel precision therapeutic targets must be identified. Our hypothesis is that the cancer proteomes of glioma tumors may contain protein variants that are linked to the aggressive pathology of the disease. To this end, we devised a novel workflow that combined variant proteomics with molecular epidemiological mining of public cancer data sets to identify 10 previously unrecognized variants linked to the risk of death in low grade glioma or GBM. We hypothesize that a subset of the protein variants may be successfully developed in the future as novel targets for malignant gliomas.
Insights
Researchers identified 10 new protein variants linked to glioma and glioblastoma survival. These findings could lead to novel precision therapies for aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Proteomics
- Cancer genomics
Background:
- Malignant gliomas, particularly glioblastomas (GBM), are aggressive brain tumors with poor prognoses.
- Current standard treatments offer limited survival benefits for GBM patients, necessitating new therapeutic strategies.
Purpose of the Study:
- To identify novel protein variants associated with the aggressive nature of gliomas.
- To explore the potential of these variants as biomarkers and therapeutic targets for malignant gliomas.
Main Methods:
- A novel workflow combining variant proteomics with molecular epidemiological analysis of public cancer datasets.
- Identification of previously unrecognized protein variants linked to patient mortality in low-grade glioma and GBM.
Main Results:
- Discovery of 10 novel protein variants associated with the risk of death in glioma and GBM patients.
- These variants represent potential new molecular targets for understanding glioma progression.
Conclusions:
- Protein variants in glioma cancer proteomes may be linked to disease aggressiveness.
- Identified variants hold promise for future development as precision therapeutic targets for malignant gliomas.
More Related Videos
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
